1st line Relapsed or Metastatic mucosal, HNSCC, not NPC

Treatment

PDL1(+)

HPV(+) Only

ENT0097
A Phase II Study of Ipilimumab in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
PI: Colevas Sponsor: National Cancer Institute (NCI)

ENT0084
Phase II Pembrolizumab +/- BNT113 in HNSCC Which is HPV+ and Expresses PD-L1
PI: Colevas Sponsor: BioNTech SE

ENT0088
Phase III Macrogliomab Combination Therapy in Head and Neck Squamous Cell Carcinoma
PI: Colevas Sponsor: Gilead Sciences, Inc.

ENT0107
Randomized Phase II Open-Label Multi-Arm Study of Tislelizumab in Combo with Investigational Agents as First-Line Treatment in Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma
PI: Khan Sponsor: BeiGene, Ltd

ENT0064
Phase Ib/II AIMP-P+arAAMP +/- Co-Admin of Fludarabine Phosphate in Recurrent Local Head & Neck Cancer
PI: Colevas Sponsor: PNP Therapeutics

ENT0088
Phase II Macrogliomab Combination Therapy in Head and Neck Squamous Cell Carcinoma
PI: Colevas Sponsor: Gilead Sciences, Inc.

PDL1(-)

Injectable Lesions

KEY

Pending
Open for Enrollment
Observational Study
Link
Optional Path
Trial Posting
Enrollment on Hold
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu